Single-Cell Analysis Transcriptomics Market Expected to Achieve 12.2% CAGR by 2029: Growth Forecast Insights

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Single-Cell Analysis Transcriptomics Market Size By 2025?
Over the past few years, the market size for single-cell analysis transcriptomics has experienced significant growth. The market, which was worth $0.97 billion in 2024, is projected to rise to $1.08 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 11.9%. This growth during the historical period has been driven by the escalating demand for personalized medicine, a rise in the occurrence of chronic and rare diseases, the advent of personalized medicine, growing demand for high-throughput sequencing, and an increase in the varied applications within cancer research.

How Big Is the Single-Cell Analysis Transcriptomics Market Size Expected to Grow by 2029?
In the coming years, rapid expansion is anticipated in the single-cell analysis transcriptomics market, which is projected to reach $1.72 billion by 2029 with a 12.2% compound annual growth rate (CAGR). This growth during the forecast period could be explained by the increased application in immunology and neurology, the rise in drug discovery and development, the broader acceptance of precision medicine, government-backed genomics research programs, and the improvement in the affordability of sequencing technologies. Key trends anticipated during the forecast period encompass advancements in microfluidics and sequencing platforms, the incorporation of artificial intelligence in data appraisal, the creation of multi-omics methodologies, innovations in single-cell isolation strategies, and an enhanced emphasis on spatial transcriptomics.

View the full report here:
https://www.thebusinessresearchcompany.com/report/single-cell-analysis-transcriptomics-global-market-report

Which Key Market Drivers Powering Single-Cell Analysis Transcriptomics Market Expansion and Growth?
The surge in the implementation of personalized medicine is set to spur the single-cell analysis transcriptomics market's expansion. Personalized medicine refers to a medical strategy that makes treatment decisions based on an individual's genetic makeup, lifestyle, and environment. The rise in the use of personalized medicine can be attributed to advancements in genetic sequencing, which allow for treatments that are specifically designed for individual genetic profiles, boosting their effectiveness. Single-cell analysis transcriptomics reveals distinct gene expression profiles, facilitating personalized treatments according to a patient's unique biological characteristics. This heightens the effectiveness of treatments, reduces side effects, and allows for early diagnosis of diseases. For example, data from the U.S.-based Personalized Medicine Coalition, in February 2024, indicated that the U.S. Food and Drug Administration greenlit 16 new personalized treatments for patients with rare conditions in 2023, a significant rise from the six approvals in 2022. As a result, the growing acceptance of personalized medicine contributes to the expansion of the single-cell analysis transcriptomics market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24400&type=smp

Which Emerging Trends Are Transforming the Single-Cell Analysis Transcriptomics Market in 2025?
Major firms in the single-cell analysis transcriptomics market are prioritizing the development of cutting-edge products such as single-cell RNA sequencing kits. These products aim to simplify workflow and offer a more profound understanding of cellular heterogeneity. The single-cell RNA sequencing kit, specifically, is a tool designed to isolate and study gene expression at the cell-by-cell level. This technology provides researchers the ability to study cellular diversity and gather information about intricate biological mechanisms. For example, Fluent BioSciences Inc., a US-based biotech company with a focus on single-cell analysis and molecular research technologies, introduced their PIPseq T2 and T20 v3.0 kits in June 2022. These kits can encapsulate up to 2,000 and 20,000 single cells or nuclei per reaction. They provide a precise, scalable and versatile transcriptomic analysis, which is perfect for studies related to low-cell diversity and large-scale solid tissue profiling. The kit also stands out for its accessibility and affordability as a single-cell RNA sequencing kit.

What Are the Emerging Segments in the Single-Cell Analysis Transcriptomics Market?
The single-cell analysis transcriptomics market covered in this report is segmented -

1) By Component: Equipment, Consumables, Software And Services
2) By Technology: Single-Cell Ribonucleic Acid (RNA) Sequencing, Microfluidics-Based Techniques, Other Technologies
3) By Application: Clinical Diagonstics, Developmental Biology, Drug Discovery, Other Applications
4) By End-User: Academic And Research Institutions, Hospitals And Diagonstic Centers, Pharmaceutical And Biotechnology Companies

Subsegments:
1) By Equipment: Ribonucleic Acid (RNA) Sequencers, Polymerase Chain Reaction (PCR) Machines, Microarray Instruments, Electrophoresis Systems, Flow Cytometers, Imaging Systems
2) By Consumables: Reagents And Kits, Ribonucleic Acid (RNA) Extraction Kits, Microarray Chips, Sequencing Chips, Complementary DNA (cDNA) Synthesis Kits, Library Preparation Kits, Enzymes And Buffers
3) By Software And Services: Data Analysis Software, Transcriptome Assembly Software, Cloud-Based Solutions, Bioinformatics Services, Data Management Tools, Custom Analysis Services, Technical Support And Training

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24400&type=smp

Who Are the Global Leaders in the Single-Cell Analysis Transcriptomics Market?
Major companies operating in the single-cell analysis transcriptomics market are Merck KGaA, Thermo Fisher Scientific Inc., Danaher Corporation, Becton dic*kinson and Company, Agilent Technologies Inc., Sartorius Aktiengesellschaft, Illumina Inc., Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., 10x Genomics Inc., Abcam Limited, Novogene Co. Ltd., Standard BioTools Inc., Akoya Biosciences Inc., Parse Biosciences Inc., Cell Microsystems Inc., Mission Bio Inc., Relation Therapeutics Ltd., CYTENA GmbH, Fluent BioSciences

Which are the Top Profitable Regional Markets for the Single-Cell Analysis Transcriptomics Industry?
North America was the largest region in the single-cell analysis transcriptomics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the single-cell analysis transcriptomics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24400

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.